Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Structural aspects of high affinity ligands for the alpha 4 beta 2 neuronal nicotinic receptor.

Dart MJ, Wasicak JT, Ryther KB, Schrimpf MR, Kim KH, Anderson DJ, Sullivan JP, Meyer MD.

Pharm Acta Helv. 2000 Mar;74(2-3):115-23.

PMID:
10812947
2.

Structure-activity studies on a novel series of cholinergic channel activators based on a heteroaryl ether framework.

Lin NH, Abreo MA, Gunn DE, Lebold SA, Lee EL, Wasicak JT, Hettinger AM, Daanen JF, Garvey DS, Campbell JE, Sullivan JP, Williams M, Arneric SP.

Bioorg Med Chem Lett. 1999 Sep 20;9(18):2747-52.

PMID:
10509928
3.

Structure-activity studies related to ABT-594, a potent nonopioid analgesic agent: effect of pyridine and azetidine ring substitutions on nicotinic acetylcholine receptor binding affinity and analgesic activity in mice.

Holladay MW, Bai H, Li Y, Lin NH, Daanen JF, Ryther KB, Wasicak JT, Kincaid JF, He Y, Hettinger AM, Huang P, Anderson DJ, Bannon AW, Buckley MJ, Campbell JE, Donnelly-Roberts DL, Gunther KL, Kim DJ, Kuntzweiler TA, Sullivan JP, Decker MW, Arneric SP.

Bioorg Med Chem Lett. 1998 Oct 6;8(19):2797-802.

PMID:
9873625
4.

Antinociceptive effects of the novel neuronal nicotinic acetylcholine receptor agonist, ABT-594, in mice.

Decker MW, Bannon AW, Buckley MJ, Kim DJ, Holladay MW, Ryther KB, Lin NH, Wasicak JT, Williams M, Arneric SP.

Eur J Pharmacol. 1998 Apr 3;346(1):23-33.

PMID:
9617748
5.

ABT-594 [(R)-5-(2-azetidinylmethoxy)-2-chloropyridine]: a novel, orally effective antinociceptive agent acting via neuronal nicotinic acetylcholine receptors: II. In vivo characterization.

Bannon AW, Decker MW, Curzon P, Buckley MJ, Kim DJ, Radek RJ, Lynch JK, Wasicak JT, Lin NH, Arnold WH, Holladay MW, Williams M, Arneric SP.

J Pharmacol Exp Ther. 1998 May;285(2):787-94.

PMID:
9580627
6.

ABT-594 [(R)-5-(2-azetidinylmethoxy)-2-chloropyridine]: a novel, orally effective analgesic acting via neuronal nicotinic acetylcholine receptors: I. In vitro characterization.

Donnelly-Roberts DL, Puttfarcken PS, Kuntzweiler TA, Briggs CA, Anderson DJ, Campbell JE, Piattoni-Kaplan M, McKenna DG, Wasicak JT, Holladay MW, Williams M, Arneric SP.

J Pharmacol Exp Ther. 1998 May;285(2):777-86.

PMID:
9580626
7.

Identification and initial structure-activity relationships of (R)-5-(2-azetidinylmethoxy)-2-chloropyridine (ABT-594), a potent, orally active, non-opiate analgesic agent acting via neuronal nicotinic acetylcholine receptors.

Holladay MW, Wasicak JT, Lin NH, He Y, Ryther KB, Bannon AW, Buckley MJ, Kim DJ, Decker MW, Anderson DJ, Campbell JE, Kuntzweiler TA, Donnelly-Roberts DL, Piattoni-Kaplan M, Briggs CA, Williams M, Arneric SP.

J Med Chem. 1998 Feb 12;41(4):407-12.

PMID:
9484491
8.

A-85380 [3-(2(S)-azetidinylmethoxy) pyridine]: in vitro pharmacological properties of a novel, high affinity alpha 4 beta 2 nicotinic acetylcholine receptor ligand.

Sullivan JP, Donnelly-Roberts D, Briggs CA, Anderson DJ, Gopalakrishnan M, Piattoni-Kaplan M, Campbell JE, McKenna DG, Molinari E, Hettinger AM, Garvey DS, Wasicak JT, Holladay MW, Williams M, Arneric SP.

Neuropharmacology. 1996 Jun;35(6):725-34.

PMID:
8887981
9.

Novel 3-Pyridyl ethers with subnanomolar affinity for central neuronal nicotinic acetylcholine receptors.

Abreo MA, Lin NH, Garvey DS, Gunn DE, Hettinger AM, Wasicak JT, Pavlik PA, Martin YC, Donnelly-roberts DL, Anderson DJ, Sullivan JP, Williams M, Arneric SP, Holladay MW.

J Med Chem. 1996 Feb 16;39(4):817-25.

PMID:
8632405
10.

Ligands for brain cholinergic channel receptors: synthesis and in vitro characterization of novel isoxazoles and isothiazoles as bioisosteric replacements for the pyridine ring in nicotine.

Garvey DS, Wasicak JT, Elliott RL, Lebold SA, Hettinger AM, Carrera GM, Lin NH, He Y, Holladay MW, Anderson DJ, et al.

J Med Chem. 1994 Dec 23;37(26):4455-63.

PMID:
7799396
11.

(S)-3-methyl-5-(1-methyl-2-pyrrolidinyl)isoxazole (ABT 418): a novel cholinergic ligand with cognition-enhancing and anxiolytic activities: II. In vivo characterization.

Decker MW, Brioni JD, Sullivan JP, Buckley MJ, Radek RJ, Raszkiewicz JL, Kang CH, Kim DJ, Giardina WJ, Wasicak JT, et al.

J Pharmacol Exp Ther. 1994 Jul;270(1):319-28.

PMID:
7913497
12.

Novel isoxazoles which interact with brain cholinergic channel receptors have intrinsic cognitive enhancing and anxiolytic activities.

Garvey DS, Wasicak JT, Decker MW, Brioni JD, Buckley MJ, Sullivan JP, Carrera GM, Holladay MW, Arneric SP, Williams M.

J Med Chem. 1994 Apr 15;37(8):1055-9. No abstract available.

PMID:
7909335
13.

Synthesis and in vitro characterization of novel amino terminally modified oxotremorine derivatives for brain muscarinic receptors.

Garvey DS, Wasicak JT, Chung JY, Shue YK, Carrera GM, May PD, McKinney MM, Anderson D, Cadman E, Vella-Rountree L, et al.

J Med Chem. 1992 May 1;35(9):1550-7.

PMID:
1578480

Supplemental Content

Loading ...
Support Center